Net product sales in SMA market: Spinraza, Zolgensma & Evrysdi

Last Update: Aug 1, 2022

in millions, $, exc. Evrysdi Q416 Q117 Q217 Q317 Q417 Q118 Q218 Q318 Q418 Q119 Q219 Q319 Q419 Q120 Q220 Q320 Q420 Q121 Q221 Q321 Q421 Q122 Q222 FY 2017 2018 2019 2020 2021
Spinraza USA 5 46 195 198 218 188 206 224 236 223 231 237 473 235 210 183 160 149 149 140 150 163 140 657 854 1164 788 588
(Biogen) ROW 0 1 8 73 144 176 217 244 234 295 258 310 70 330 284 312 338 372 350 304 291 309 291 227 870 933 1,264 1,317
Global Spinraza revenue 5 47 203 271 362 364 423 468 470 519 488 547 543 565 495 494 498 521 500 444 441 473 431 884 1,724 2,097 2,052 1,905
Zolgensma USA - - - - - - - - - - 12 150 145 126 105 122 106 119 106 126 118 113 123 - - 307 459 469
(Novartis) ROW - - - - - - - - - - 3 10 41 44 100 169 148 200 209 249 224 250 256 - - 54 461 882
Global Zolgensma revenue - - - - - - - - - - 15 160 186 170 205 291 254 319 315 375 342 363 379 - - 361 920 1,351
Evrysdi USA (in CHf) - - - - - - - - - - - - - - - 8 47 79 87 102 97 109 118 - - - 55 365
(Roche) EU (in CHf) - - - - - - - - - - - - - - - - - - 27 35 51 68 84 - - - 0 113
JPN (in CHf) - - - - - - - - - - - - - - - - 0 0 0 3 16 17 21 - - - - 19
International (in CHf) - - - - - - - - - - - - - - - - 0 1 49 13 42 32 51 - - - 0 105
Global Evrysdi revenue - - - - - - - - - - - - - - - 8 47 80 163 153 206 226 274 - - - 55 602
USA Spinraza share 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 95% 61% 77% 65% 67% 58% 50% 42% 43% 37% 40% 41% 36% 100% 100% 79% 60% 40%
Zolgensma share - - - - - - - - - - 5% 39% 23% 35% 33% 39% 33% 34% 30% 33% 32% 29% 32% - - 21% 35% 32%
Evrysdi share - - - - - - - - - - - - - - - 3% 16% 25% 27% 29% 28% 30% 32% - - - 4% 27%
ROW Spinraza share - 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 97% 63% 88% 74% 65% 70% 65% 55% 50% 46% 45% 41% 100% 100% 95% 73% 54%
Zolgensma share - - - - - - - - - - 1% 3% 37% 12% 26% 35% 30% 35% 33% 41% 35% 36% 36% - - 5% 27% 36%
Evrysdi share - - - - - - - - - - - - - - - - - 0% 13% 9% 19% 18% 23% - - - 0% 11%
Net product sales of Spinraza, Zolgensma and Evrysdi, by quarter and year. Spinraza U.S. price: $810,000 initial year, $405,000/yr maintenance. Zolgensma U.S. price: $2,100,000 per patient (payments of $425,000 over 5 yrs). Evrysdi U.S. price: $100,000/yr (children who weigh up to 15 pounds (~2 yrs age), capped at $340,000/yr (20 kg, ages 2 and above). Q222: Second quarter, 2022. ROW: Rest of world (ex-USA). Market share % takes into account Fx conversion. Note: Spinraza, Zolgensma and Evrysdi labels do not overlap completely.


Have feedback? Tweet or DM me @blackseedbio on Twitter, or contact me here.

If you want to get notified when updates are available, please consider subscribing.

SUBSCRIBE